Clinical Trials Logo

Pneumonia, Ventilator-Associated clinical trials

View clinical trials related to Pneumonia, Ventilator-Associated.

Filter by:

NCT ID: NCT04739878 Completed - Clinical trials for Ventilator Associated Pneumonia

SUBSUS (SUBglottic Secretion at Ultrasound Score)

SUBSUS
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

To compare the performance of ultrasound in detecting subglottic secretion above the ETT tube cuff in comparison to computed tomography (CT) scan.

NCT ID: NCT04739748 Completed - Clinical trials for Ventilator Associated Pneumonia

Prognostic Biomarkers in Predicting Mortality in Respiratory Patients With Ventilator-Associated Pneumonia

Start date: April 6, 2018
Phase:
Study type: Observational

The aim of this study is to evaluate prognostic efficiency RDW and NLR for mortality prediction in respiratory patients with VAP.

NCT ID: NCT04700202 Completed - Clinical trials for Ventilator-associated Pneumonia

Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit

Start date: June 30, 2020
Phase:
Study type: Observational

Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.

NCT ID: NCT04563104 Completed - Clinical trials for Ventilator Associated Pneumonia

Lung Ultrasound in Procalcitonin- Guided Antibiotic Discontinuation in Ventilator Associated Pneumonia

Start date: October 1, 2020
Phase:
Study type: Observational

Ventilator Associated pneumonia (VAP) is associated with longer ICU length of stay, prolonged mechanical ventilation, and increased use of antimicrobials, health-care cost and mortality . Acute respiratory infections (ARIs) comprise a large and heterogeneous group of infections, including bacterial infections, viral infections, and infections of other etiologies. Early initiation of adequate antibiotic therapy is the cornerstone in the treatment. However, overuse of antibiotics and prolonged duration of antibiotic therapy in patients with bacterial ARIs in the hospital and intensive care setting is associated with increased resistance for common bacteria, high costs, and adverse drug reactions.

NCT ID: NCT04527276 Completed - Clinical trials for Ventilator Associated Pneumonia

Reducing the Incidence of VAP in Critically Ill Children and Assessment of Oral Care With CHX

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

This was a single-centered, randomized, placebo-controlled double-blind clinical trial conducted in the pediatric intensive care unit (PICU), in patients who were aged 1 month to 18 years, needing MV for at least 48 hours, to evaluate the effect of Chlorhexidine (CHX) on Ventilator-associated pneumonia (VAP) incidence and to determine VAP risk factors.

NCT ID: NCT04505202 Completed - Clinical trials for Ventilator Associated Pneumonia

Effect of Chlorhexidine-Induced Oral Care on Ventilator-Related Some Respiratory System Complications

Start date: April 15, 2019
Phase: N/A
Study type: Interventional

Ventilator-associated pneumonia and ventilator-associated treakeabronchitis in respiratory tract infections associated with ventilator are common infections in intensive care unit and cause significant morbidity, mortality and health expenditures in nosocomial infections. Adequate and effective oral care by nurses in intensive care patients, possible complications, intensive care unit stay in the intensive care unit and is very important in terms of mortality.

NCT ID: NCT04467892 Completed - Clinical trials for Ventilator Associated Pneumonia

Low Versus High Corticosteroid Use in Ventilator Associated Pneumonia

Start date: January 2, 2018
Phase: Phase 2
Study type: Interventional

patients who had >3 on Murray score and >6 on CPIS allocated randomly in two groups 120 patients in each. Group A received 30 mg/kg methyl-prednisolone slowly intravenous in 250 mL normal saline every 8 hours for only 48 hours while group B received 1 mg/kg/day methyl-prednisolone divided to three doses given every 8 hours for two weeks. Duration of the study last 16 days, Morbidity considered if no improvement in any or all clinical parameters of both Murray and CPIS scores and failure of weaning of patients from the ventilator at the studied period.

NCT ID: NCT04402359 Completed - Clinical trials for Ventilator Associated Pneumonia

Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS

Start date: July 5, 2018
Phase:
Study type: Observational [Patient Registry]

This was a prospective double blind study conducted on 200 polytrauma patients admitted to King Abdul-Aziz Specialized Hospital, Taif, KSA between July 2018 and December 2019 in surgical ICU. All patients were having severe chest trauma, contused lungs either with or without severe head trauma.

NCT ID: NCT04397952 Completed - Clinical trials for Ventilator Associated Pneumonia

Endotracheal Tube Cuff Pressure Measurement

Start date: November 1, 2017
Phase:
Study type: Observational [Patient Registry]

The effect of endotracheal cuff pressure measurement technique for preventing ventilatory associated pneumonia.

NCT ID: NCT04335539 Completed - Sepsis Clinical Trials

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Start date: August 21, 2020
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are: - To assess the safety and tolerability of cefiderocol after single-dose administration in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed aerobic Gram-negative bacterial infections - To assess the pharmacokinetics (PK) of cefiderocol after single-dose administration of cefiderocol in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed aerobic Gram-negative bacterial infections - To assess the safety and tolerability of cefiderocol after multiple-dose administration in hospitalized paediatric participants 3 months to < 12 years of age with suspected or confirmed aerobic Gram-negative bacterial infections - To assess the PK of cefiderocol after multiple-dose administration in hospitalized paediatric participants 3 months to < 12 years of age with suspected or confirmed aerobic Gram-negative bacterial infections